Equities research analysts expect Quanterix Corp (NASDAQ:QTRX) to announce $14.18 million in sales for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Quanterix’s earnings, with the lowest sales estimate coming in at $13.30 million and the highest estimate coming in at $15.15 million. Quanterix posted sales of $10.88 million in the same quarter last year, which suggests a positive year over year growth rate of 30.3%. The company is scheduled to issue its next quarterly earnings report on Monday, March 16th.
According to Zacks, analysts expect that Quanterix will report full-year sales of $55.14 million for the current fiscal year, with estimates ranging from $54.63 million to $55.87 million. For the next financial year, analysts anticipate that the business will report sales of $70.84 million, with estimates ranging from $68.05 million to $74.00 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that cover Quanterix.
Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. The firm had revenue of $14.94 million for the quarter, compared to analysts’ expectations of $12.52 million. Quanterix had a negative net margin of 75.78% and a negative return on equity of 54.74%.
Shares of QTRX stock opened at $25.75 on Friday. The stock has a market cap of $736.66 million, a price-to-earnings ratio of -15.42 and a beta of 1.31. The company has a quick ratio of 7.00, a current ratio of 7.61 and a debt-to-equity ratio of 0.06. Quanterix has a fifty-two week low of $19.08 and a fifty-two week high of $36.15. The firm’s 50 day moving average price is $23.80 and its two-hundred day moving average price is $24.90.
In other news, Director Martin D. Madaus sold 1,600 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $25.40, for a total transaction of $40,640.00. Following the transaction, the director now directly owns 8,149 shares of the company’s stock, valued at $206,984.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Mark T. Roskey sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $24.04, for a total transaction of $120,200.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,376 shares of company stock worth $1,103,218. Corporate insiders own 30.80% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers increased its stake in shares of Quanterix by 13.1% in the third quarter. Rhumbline Advisers now owns 12,721 shares of the company’s stock worth $279,000 after buying an additional 1,469 shares during the last quarter. California Public Employees Retirement System increased its stake in shares of Quanterix by 16.8% in the third quarter. California Public Employees Retirement System now owns 15,963 shares of the company’s stock worth $351,000 after buying an additional 2,297 shares during the last quarter. Northern Trust Corp increased its stake in shares of Quanterix by 2.6% in the second quarter. Northern Trust Corp now owns 100,434 shares of the company’s stock worth $3,394,000 after buying an additional 2,544 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Quanterix by 116.4% in the second quarter. Royal Bank of Canada now owns 6,285 shares of the company’s stock worth $213,000 after buying an additional 3,380 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY bought a new stake in shares of Quanterix in the third quarter worth $78,000. 67.50% of the stock is currently owned by institutional investors and hedge funds.
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Further Reading: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.